00000000nam 2200000zi 4500
0019.954007
003CaOODSP
00520250822145054
006m     o  d f      
007cr cn ||||||||
008250812s2024    oncd    obs  f000 0 eng d
040 |aCaOODSP|beng|erda|cCaOODSP
0410 |aeng|afre
043 |an-cn---
0861 |aH82-57/2024-PDF
1001 |aZhang, Yvonne, |eauthor.
24510|aCost drivers for Canada's public and private drug plans during the COVID-19 pandemic : |ba 2019-2022 comparative analysis / |cYvonne Zhang = Facteurs de coût des régimes d'assurance-médicaments publics et privés du Canada pendant la pandémie de COVID-19 : une analyse comparative 2019-2022 / Yvonne Zhang.
24611|aFacteurs de coût des régimes d'assurance-médicaments publics et privés du Canada pendant la pandémie de COVID-19 : |bune analyse comparative 2019-2022
264 1|a[Ottawa] : |bPatented Medicine Prices Review Board = Conseil d'examen du prix des médicaments brevetés, |c[2024]
300 |a1 online resource (1 unnumbered page) : |bgraphs
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aCaption title.
500 |a"NPDUIS, National Prescription Drug Utilization Information System, "Supporting health care decision making in Canada" = SNIUMP, Le Système national d'information sur l'utilisation des médicaments prescrits, « Appuyer les décisions en matière des soins de santé au Canada »"
504 |aIncludes bibliographical references.
520 |a"Canadian public drug plans and private insurers together account for over three quarters of all prescribed drug spending in Canada. This poster sheds light on the differences and similarities between key cost pressures for public and private drug plans, differentiating between short-term effects and those with longer-lasting impacts. The study spans from 2019, before the COVID-19 pandemic, to 2022, with a retrospective look at recent trends and highlights the impact of the pandemic on Canadian drug spending"--Introduction, page [1].
546 |aText in English and French.
650 0|aPharmaceutical policy|zCanada|vStatistics.
650 0|aPharmaceutical services insurance|zCanada|xCosts|vStatistics.
650 0|aCOVID-19 Pandemic, 2020-2023|xEconomic aspects|zCanada|vStatistics.
655 7|aStatistics|2lcgft
7101 |aCanada. |bPatented Medicine Prices Review Board, |eissuing body.
788 |tCost drivers for Canada's public and private drug plans during the COVID-19 pandemic : |efre|w(CaOODSP)9.954006
85640|qPDF|s538 KB|uhttps://publications.gc.ca/collections/collection_2025/cepmb-pmprb/H82-57-2024.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/patented-medicine-prices-review/services/npduis/analytical-studies/posters/cahspr2024-cost-drivers.html